The DOI matches its Crossref record; the references it cites are not checked yet.
An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Abstract
Introduction: The prevalence of obesity is increasing worldwide and associated conditions, particularly type 2 diabetes mellitus (T2DM), also show increasing prevalence. Lifestyle intervention should be the first line of management for obesity but additional pharmacotherapy is often required and bariatric surgery is appropriate in more severe cases. Drugs acting as glucagon-like peptide-1 receptor agonists (GLP-1RAs) developed for the management of T2DM reduce body weight and liraglutide is the first GLP-1RA to be approved for the treatment of obesity in patients with and without T2DM.Areas covered: In this review of relevant published material, the authors summarize the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of liraglutide for the treatment of obesity.Expert opinion: Liraglutide effectively reduces body weight and body fat through mechanisms involving reduced appetite and lowered energy intake, independent of its glucose-lowering effects. Like most of the other medications currently available for obesity, liraglutide has some common adverse effects, although generally not serious ones. Liraglutide has additional benefits in reducing cardiovascular events in patients with T2DM but the cost and the need for daily injections may limit its use in obesity. Newer GLP-1RAs, such as semaglutide, or other drugs in development for obesity may have advantages over liraglutide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to lowering blood sugar levels, liraglutide helps to reduce body weight by suppressing appetite and reducing energy intake,84,85”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [84]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 78 · Cited by 65
Metadata
- Authors
- Lin, C.-H., Shao, L., Zhang, Y.-M., Tu, Y.-J., Zhang, Y., Tomlinson, B., Chan, P., & Liu, Z.
- Affiliations
- Taipei Medical University (TW)
- Tongji University (CN)
- Macau University of Science and Technology (MO)
- Wan Fang Hospital (TW)
- Corresponding author
- Chan, Paul
- Liu, Zhongmin
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2019-12-02
- Volume
- 21
- Issue
- 3
- Pages
- 275-285
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2992083029
- Cited by
- 65
- References
- 78
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 18 · 2023: 14 · 2022: 13 · 2021: 5 · 2020: 4
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- liraglutide, obesity, GLP-1 receptor agonists, type 2 diabetes, weight loss, pharmacokinetics, pharmacodynamics, adverse effects, cardiovascular events, semaglutide, appetite suppression
- MeSH terms
- Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Body Weight, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. https://app.cochat.ai/papers/10.1080/14656566.2019.1695779
- The paper
- Lin, C.-H., Shao, L., Zhang, Y.-M., Tu, Y.-J., Zhang, Y., Tomlinson, B., Chan, P., & Liu, Z. (2020). An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2019.1695779
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.